Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 109.00 | |
2 mg | In stock | $ 158.00 | |
5 mg | In stock | $ 249.00 | |
10 mg | In stock | $ 482.00 | |
25 mg | In stock | $ 789.00 | |
50 mg | In stock | $ 1,080.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 269.00 |
Description | Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4). |
Targets&IC50 | EGFR:0.3 nM, Flt4:8.7 nM, KDR:1.5 nM, ErbB2:16 nM |
In vitro | Tesevatinib was inactive against a panel of 10 tyrosine kinases (including the insulin and the insulin-like growth factor-1 receptor) and 55 serine-threonine kinases (including cyclin-dependent kinases, stress-activated protein kinases, and protein kinase C isoforms). Tesevatinib inhibits cellular proliferation and EGFR pathway activation in the erlotinib-resistant H1975 cell line that harbors a double mutation (L858R and T790M) in the EGFR gene. In A431 cells, Tesevatinib reduces cell viability (IC50: 13 nM). |
Cell Research | Growth inhibition of H1975 and A431 cells by increasing concentrations of Tesevatinib is determined by seeding 5000 cells per well in 96-well plates. The following day, cells are washed once with low-serum RPMI 1640 (0.1% fetal bovine serum, 1% nonessential amino acids, and 1% penicillin/streptomycin), after which 90 μL of the low-serum RPMI 1640 is added. Tesevatinib is diluted to 10 times the test concentrations and 10 μL are added to triplicate wells for a 72-h incubation. Cell viability is determined. |
Animal Research | Tumor-bearing mice are given either Tesevatinib, erlotinib, or gefitinib at 100 mg/kg and tumors are harvested 1 to 72 h later. Half an hour before the respective time point, EGF (50 μg/mouse) is given via i.v. bolus injection with tumors dissected 30 min later and tumor extracts are prepared by homogenization in 10 volumes of ice-cold lysis buffer. Lysates are clarified by centrifugation and EGFR tyrosine phosphorylation levels are determined by ELISA. |
Synonyms | KD-019, XL-647, EXEL-7647 |
Molecular Weight | 491.39 |
Formula | C24H25Cl2FN4O2 |
CAS No. | 781613-23-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (61.05 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tesevatinib 781613-23-8 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR VEGFR FLT Ephrin Receptor EXEL7647 HER1 XL647 Inhibitor KD-019 Vascular endothelial growth factor receptor XL-647 KD019 Epidermal growth factor receptor KD 019 EXEL-7647 ErbB-1 XL 647 EXEL 7647 inhibit inhibitor